Table 2.

Studies using Ad5/F35-based vectors in various cancers.

Ad5/F35 vectors alone		Tumor targeted	Effect compared to Ad5 vectors alone	Studies	References
		Head and neck cancer	Effective	In vitro/in vivo	83,84
		Melanoma cells	Effective	In vitro/in vivo	83
		Glioblastoma	Effective	In vitro/in vivo	85
		B-lymphocytic Malignancies	Effective	In vitro/in vivo	86
		Renal cancer cells	Effective	In vitro	42
Ad5/F35 mediated gene therapy	gene	Tumor targeted	Effect compared to Ad5 mediated genetherapy	Studies	References
	TERT	Head and neck cancer	Enhanced	In vitro/in vivo	87
	TRAIL	1) Glioblastoma	Enhanced	In vitro/in vivo	88
		2) Leukemia	Enhanced	In vitro/in vivo	89
	XAF1	Hepatocellular carcinoma	Enhanced	In vitro/in vivo	90
	p53	1)Hepatocellular carcinoma	Enhanced	In vitro/in vivo	91
		2)Breast cancer	Enhanced	In vitro/in vivo	92
		1) Lung cancer	Enhanced	In vitro	93
	MKp-E1	2) Mesothelioma	similar	In vitro	94
			Enhanced/similar	In vitro	95
			enhanced	in vivo	95
		3) Bladder cancer	Enhanced	In vitro	96
		4) Osteosarcoma	Enhanced	In vitro/in vivo	97
	Hep27	Renal cancer	Enhanced	In vitro/in vivo	98
Ad5/F35 with chemotherapy	Drugs	Tumor targeted	Effect compared to Ad5 with chemotherapy	Studies	References
Ad5/F35-M/V-HF	DTIC	Melanoma	Enhanced	In vitro/in vivo	99
Ad5/F35-tk	GCV	Colorectal cancer	Enhanced	In vitro/in vivo	100
Ad5/F35	Cisplatin	Head and neck cancer	Enhanced	in vivo	101
Ad5/F35 with radiation	Radiation	Tumor targeted	Effect compared to Ad5 with radiation	Studies	References
Ad5/F35		Head and neck cancer	Enhanced	in vivo	101
Ad5/F35-APE1 siRNA		Colorectal cancer	Enhanced	In vitro/in vivo	102